MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Cost of Revenue 2011-2026 | CSII
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.4 M | 61.1 M | 48.8 M | 47.7 M | 39.5 M | 39.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.4 M | 39.4 M | 50 M |
Quarterly Cost of Revenue Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.5 M | 16.7 M | 35.2 M | 14.8 M | 18.1 M | 14.3 M | 32.4 M | 14 M | 13.9 M | 12.6 M | 13.9 M | 12.2 M | 13.7 M | 12.7 M | 13.7 M | 12.7 M | 11.5 M | 10.6 M | 11.5 M | 10.6 M | 9.5 M | 9.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.2 M | 9.2 M | 15.1 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
13.7 M | - | 1.37 % | $ 20.5 M |  USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 38.78 | -1.25 % | $ 5.78 K | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.15 | 4.22 % | $ 585 M |  Israel |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 9.69 | 3.09 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.15 | 4.01 % | $ 155 M |  France |
 |
Electromed
ELMD
|
14 M | $ 24.26 | 1.17 % | $ 205 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 43.13 | -0.43 % | $ 1.34 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 29.17 | -2.21 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.31 | 4.42 % | $ 115 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.53 | 0.68 % | $ 54.5 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.79 | -1.24 % | $ 43 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 183.14 | 0.27 % | $ 13.7 B | USA |
 |
Inari Medical
NARI
|
44.5 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 3.99 | 7.7 % | $ 845 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 113.59 | 0.01 % | $ 198 B | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.58 | -0.18 % | $ 878 M | Israel |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 72.75 | -1.49 % | $ 108 B | USA |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 105.22 | 0.89 % | $ 1.33 B | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.42 | -0.7 % | $ 22.9 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.31 | 16.67 % | $ 1.4 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 13.05 | 0.23 % | $ 1.96 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 85.73 | 0.55 % | $ 50.1 B | USA |